Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Der Anaesthesist 49 (2000), S. 187-195 
    ISSN: 1432-055X
    Keywords: Schlüsselwörter Herzstillstand ; Progressive Muskeldystrophie Typ Duchenne und Becker ; Inhalationsanästhetika ; Succinylcholin ; Rhabdomyolyse ; Key words Duchenne and Becker type muscular dystrophy ; Cardiac arrest ; Succinylcholine ; Volatile anaesthetics ; Rhabdomyolysis
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Abstract During the last 30 years a great number of case reports presented severe anaesthetic complications with sudden cardiac arrest in patients with muscular dystrophies, mostly unsuspected at the time of the event. As succinylcholine was involved in the majority of the intractable incidents with lethal outcome the Food and Drug Administration (FDA) of the United States recommended a warning of the administration of succinylcholine in young children and adolescents in 1992 and an extensive international discussion on the routine use of succinylcholine in paediatric anaesthesia. Epidemiological studies on this issue are rare. We projected an inquiry about the incidence rate and type of severe anaesthetic complications in an utmost large number of patients and families with Duchenne (DMD) and Becker type (BMD) muscular dystrophy. Methods: With the approval of the ethic committee of the university Witten/ Herdecke and informed consent of the participants we investigated all patients and families who were diagnosed, controlled and treated for DMD or BMD as inpatients or outpatients in a „Muscle Centre” since 1983. The questionnaire asked for the number of patients per family, classification of the disease DMD or BMD, number and date of anaesthetics in the patients and eventual complications, anaesthetics and eventual complications in the parents, siblings and relatives and the occurrence of malignant hyperthermia (MH) in the family or relatives. Statistical assessments were done by Fisher’s exact test for stratified 2×2 tables and Zelen’s test for homogeneity of odds ratios. Results: 200 out of 224 questionnaires could be evaluated. The diagnosis was confirmed by molecular genetic and immunohistochemical investigations. In 147 families it turned out to be DMD, in 53 families BMD. The 212 male and 9 female patients in the 200 families were given 444 anaesthetics. Sudden cardiac arrest occurred in 6 patients, all successfully resuscitated. Nine less severe incidents consisted of fever, symptoms of rhabdomyolysis (CK-elevation, dark coloured urine, hyperkalemia) and masseter spasm. The statistical assessment revealed that the occurrence of an event was highly dependent whether the diagnosis of muscular dystrophy was established or not (p〈0.0001, Fisher’s exact test). All six cardiac arrests occurred in the 45 families with undiagnosed disease and no event happened in the 134 families with already known DMD/BMD. There was evidence that the number of anaesthetics without prior establishment of the diagnosis decreased after 1992 (p=0.004, Fisher’s exact test). Conclusions: Our results demonstrate that severe incidents and cardiac arrests occurred only in young children with undiagnosed DMD or BMD who received inhalational agents and succinylcholine. A cardiac arrest in 6 out of 200 families was found much more frequently than in the normal paediatric population (about 1:1000 to 1:3000). The decrease of events after 1992 (warning of the FDA) and disappearance of sudden cardiac arrests in our group of patients might be due to the world wide discussion on routine use of succinylcholine in children or the much earlier establishment of the diagnosis in our population. An early diagnosis of DMD and BMD and the avoidance of the triggering agents succinylcholine and volatile anaesthetics can reduce the risk of severe anaesthetic complications.
    Notes: Zusammenfassung Ziel unseres Projekts war es, Inzidenz und Art schwerer Narkosezwischenfälle bei Patienten mit Muskeldystrophie Typ Duchenne (DMD) oder Becker (BMD) zu erfassen. Die Epidemiologie derartiger Komplikationen ist weitgehend unbekannt, da in der internationalen Literatur überwiegend Einzelfallberichte von Zwischenfällen mit Asystolie und Rhabdomyolyse vorliegen. Methodik: Mit Genehmigung der Ethikkommission erfassten wir mittels einer Fragebogenerhebung bei Patienten und Familien mit DMD oder BMD, die in unserem Muskelzentrum untersucht und behandelt wurden, folgende Daten: Anzahl der Patienten pro Familie, Klassifikation der Erkrankung, Anzahl und Zeitpunkt der Narkosen sowie eventueller Zwischenfälle bei Patienten, Eltern, Geschwistern und Verwandten. Ergebnisse: In den 200 Familien mit 444 Narkosen bei 221 Patienten (212 Jungen und 9 Mädchen) fanden wir 15 schwere Narkosezwischenfälle, sechsmal mit Asystolie. Zum Zeitpunkt des Zwischenfalls waren die Kinder im Durchschnitt 3,7 Jahre alt und die Diagnose in allen Fällen noch nicht bekannt. Nur zwei Zwischenfälle traten nach 1992 auf, also nach der Diskussion um die Routineverwendung von Succinylcholin bei Kindern. Schlußfolgerungen: Eine frühe Diagnosestellung und die strikte Vermeidung von Succinylcholin und Inhalationsanästhetika können bei Patienten mit den Dystrophinopathien DMD und BMD schwere Narkosezwischenfälle mit Asystolie und Rhabdomyolyse verhindern.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1440
    Keywords: Duodenal ulcer healing ; Acid secretion ; Cimetidine pharmacokinetics ; Treatment response
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary In a prospective trial 37 duodenal ulcer patients were treated daily with 1 g cimetidine. Personal and clinical data were obtained for all patients, acid secretion studies performed before and during treatment, and pharmacokinetic parameters of cimetidine determined. The healing rate after 4 weeks was 64.9% (24 patients). Non-Responders included a higher proportion of smokers, patients with a history of ulcer and previous treatment with H2-receptor antagonists than Responders. Basal acid output (BAO) and peak acid output (PAO) values were not different between the two groups, nor was the reduction of BAO and PAO under cimetidine. However, more Responders had complete suppression of BAO than Non-Responders. A correlation existed in both groups between cimetidine plasma concentration and PAO suppression but not with BAO suppression. Regular drug intake (compliance) was found in about 90% in both groups. Cimetidine bioavailability parameters were identical in both groups, but Non-Responders had a higher peak concentration and a shorter time of peak concentration. Discriminant analysis enabled a prediction of treatment response in 89.2% of the patients by using five factors: time of peak concentration of cimetidine, previous H2-receptorantagonist treatment, peak concentration, smoking, and alcohol use. Prediction of treatment response is increased by use of drug related variables.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    Intensive care medicine 20 (1994), S. 268-271 
    ISSN: 1432-1238
    Keywords: Nitrendipine ; Vial ; Nifedipine ; Hypertensive emergency
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Objective To present the efficacy and tolerability of a new oral dosage form of the calcium antagonist nitrendipine compared to nifedipine capsules in patients with hypertensive emergency. Design Multicenter randomized double blind clinical study. Setting 23 study centres (hospitals) in Germany. Patients 161 patients between 20 and 70 years with acutely elevated blood pressure (systolic 200–250 mmHg, diastolic between 110–140 mmHg) with and without concomitant clinical symptoms. Interventions Double blind treatment with 10 mg nifedipine or 5 mg nitrendipine. Nifedipine was administered as capsules, nitrendipine was given from a small plastic tube (vial), containing 1 ml alcoholic solution. Every patient received in addition to the test medication a placebo corresponding to the other product. Patients with insufficient treatment after 45 min were given either an additional capsule of 10 mg nifedipine or a further vial containing 5 mg nitrendipine according to their group and maintaining the double dummy procedure. Measurements and results Blood pressure and heart rate were measured repeatedly during 4 h, before and 90 min after beginning of the treatment a 12 channel resting ECG was recorded. At 45 min after administration the blood pressure had fallen significantly from 216.0/117.4 mmHg to 170.0/93.3 mmHg under nifedipine and from 216.9/117.3 mmHg to 177.4/94.4 mmHg under nitrendipine. 61.6% of the nifedipine patients and 58.8% of the nitrendipine patients had already reached blood pressure values 〈180/100 mmHg after 45 min and in both groups 83% of these patients were still in this limit at the end of the observation period after 4 h. Tolerability was very good in both groups. Conclusion The new dosage form of nitrendipine (vial with 1 ml of alcoholic solution) represents an alternative in the treatment of hypertensive emergency.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...